<code id='3721088256'></code><style id='3721088256'></style>
    • <acronym id='3721088256'></acronym>
      <center id='3721088256'><center id='3721088256'><tfoot id='3721088256'></tfoot></center><abbr id='3721088256'><dir id='3721088256'><tfoot id='3721088256'></tfoot><noframes id='3721088256'>

    • <optgroup id='3721088256'><strike id='3721088256'><sup id='3721088256'></sup></strike><code id='3721088256'></code></optgroup>
        1. <b id='3721088256'><label id='3721088256'><select id='3721088256'><dt id='3721088256'><span id='3721088256'></span></dt></select></label></b><u id='3721088256'></u>
          <i id='3721088256'><strike id='3721088256'><tt id='3721088256'><pre id='3721088256'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:35
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Listen: Biogen's situation, Wegovy's risks, & biotech insider trading
          Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

          SammyKimballforSTATWhydoCEOstalklikethat?Dobiotechstocktipsmakegoodgifts?AndwhatdoAnthonyFauciandSté

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          After gene therapy, two congenitally deaf children hear for the first time

          AdobeTwocongenitallydeafchildrencanhearforthefirsttimeafterbeingtreatedwithgenetherapy,accordingtoda